StartPRENW • NASDAQ
Prenetics
0,010 $
30. sep., 14.20.26 GMT-4 · USD · NASDAQ · Ansvarsfraskrivelse
Værdipapir børsnoteret i USA
Seneste lukkekurs
0,012 $
Dagsinterval
0,010 $ - 0,012 $
Årsinterval
0,0042 $ - 0,060 $
Markedsværdi
53,64 mio. USD
Gns. volumen
143,08 t
Markedsnyheder
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
(USD)mar. 2024År til år-ændring
Indtægt
6,41 mio.-63,77 %
Driftsudgifter
12,94 mio.-35,05 %
Nettoindtægt
-8,57 mio.21,92 %
Overskudsgrad
-133,60-115,48 %
Earnings per share
EBITDA
-8,06 mio.25,95 %
Effektiv afgiftssats
3,07 %
Samlede aktiver
Samlede passiver
(USD)mar. 2024År til år-ændring
Kontanter og korttidsinvesteringer
71,26 mio.-62,57 %
Samlede aktiver
243,59 mio.-16,31 %
Samlede passiver
40,82 mio.-29,02 %
Samlet egenkapital
202,76 mio.
Shares outstanding
12,22 mio.
Kurs/indre værdi
0,00
Afkast af aktiver
-9,20 %
Afkast af kapital
-10,98 %
Nettoændring i likviditet
(USD)mar. 2024År til år-ændring
Nettoindtægt
-8,57 mio.21,92 %
Pengestrøm fra drift
Pengestrøm fra investering
Pengestrøm fra finansiering
Nettoændring i likviditet
Fri pengestrøm
Om
Prenetics is a health sciences company headquartered in Hong Kong with a significant presence in the United States. It is best known for its innovations in consumer and clinical health, focusing on early detection, prevention, and treatment of diseases, particularly cancer. Prenetics' consumer initiatives are spearheaded by IM8, a health and wellness brand. Another key offering is CircleDNA, which utilizes next-generation sequencing technology to provide comprehensive DNA testing for consumers, offering insights into health, wellness, and genetic predispositions. The company's clinical arm includes Insighta, a joint venture focused on developing multi-cancer early detection technologies. Additionally, ACT Genomics develops and provides a variety of genomic profiling panels, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests, tailored to meet specific clinical needs. ACTLiquid Pro, a sequencing-based liquid biopsy assay, and ACTMonitor, which tracks drug resistance, treatment response, and cancer recurrence in real-time, are among its notable products. ACT Risk offers management solutions for assessing and mitigating cancer risks. Wikipedia
Grundlagt
2014
Ansatte
322
Søgning
Ryd søgning
Luk søgning
Google-apps
Hovedmenu